Tom Hochuli (Vibalogics)
November 12, 2020 07:11 AM EST
Outsourcing
Cell/Gene Tx

Un­der a new CEO, Ger­man CD­MO Viba­log­ics bets $150M and 110,000 square feet on the gene ther­a­py rev­o­lu­tion

Jason Mast

Editor

Viba­log­ics start­ed out 18 years ago mak­ing vac­cines for chick­ens. Now they’re look­ing to dri­ve the gene and cell ther­a­py rev­o­lu­tion — and make a few …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Stephen Squin­to's JPM life sci­ences team is rais­ing a new fund for lat­er-stage com­pa­nies

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

sponsored

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

A service from the Financial Times